VISIT OUR COVID-19 HUB

Your Health
GettyImages-1208505315_790x500_1_0.png
GettyImages-1208505315_1000x450_0_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

Empowering Patients by Closing the Health Literacy Gap

Your Health
medical_information_790x500.png
medical_information_1000x450.jpg

Empowering Patients by Closing the Health Literacy Gap

Knowledge is power. By making health information easier to understand, we're working to help patients make meaningful decisions about their health.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Our People
aida_habtezion_380x700.png
Aida-1000x450_1.jpg

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Changing careers in the middle of a pandemic is no small endeavor. But when Aida Habtezion, M.D., learned about the opportunity to serve as Pfizer’s new Chief Medical Officer, she couldn’t pass it up.

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Our Purpose
IP-Pact tile image mobile
IP-Pact tile image

Latest News

Study explores combination in patients with DNA damage response alterations before prostate cancer becomes castration resistant Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared…